Document is current
Any future updates will be listed below
-
Authors
Bhimani, Jenna
O’Connell, Kelli
Gallagher, Grace B.
Blinder, Victoria S.
Burganowski, Rachael
Ergas, Isaac J.
Griggs, Jennifer J.
Heon, Narre
Jinna, Sankeerth
Kolevska, Tatjana
Kotsurovskyy, Yuriy
Kroenke, Candyce H.
Laurent, Cecile. A.
Liu, Raymond
Nakata, Kanichi G.
Persaud, Sonia
Roh, Janise M.
Tabatabai, Sara
Valice, Emily
Wang, Peng
Bandera, Elisa V.
Aiello Bowles, Erin J.
Kushi, Lawrence H.
Kantor, Elizabeth D.
-
Funding
Funding for this research was provided by:
National Cancer Institute (R50CA211115, U24CA171524, R37CA222793)
Geoffrey Beene
- License Information
-
More Information
Article History
Received: 30 April 2025
Accepted: 8 September 2025
First Online: 29 October 2025
Competing interests
: Dr. Wang was former employee of Daiichi Sankyo, Inc (6/2022-4/2023). Dr. Bandera served as member of Pfizer’s Advisory Board to enhance minority participation in clinical trials (7/2021-8/2023). Dr. Liu served as a member of Pfizer’s think tank on real-world evidence sponsored by Pfizer on 11/28/23. Dr. Liu’s research funding (inst) unrelated to this current work: Genentech, AstraZeneca, Exact Sciences, Biotheranostics, Beigene, and Bristol Myers Squibb. All other authors have no competing interests to declare.
